IL-6 x CK1α x TNF-α x IKZF1 x IL-2 x IFNγ x CRBN x IKZF3 x DNMT1

To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors.
To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients.
To evaluate the hematological improvement rate.
To evaluate the cytogenetic response rate.
To evaluate the Progression free survival (PFS).
To assess Quality of life.